C8, while metabolites hydroxy-dabrafenib and desmethyl-dabrafenib are CYP3A4 substrates.
Daclatasvir: (Moderate) Use caution if coadministration of ribociclib with daclatasvir is necessary, as the systemic exposure of daclatasvir may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and daclatasvir is a CYP3A4 substrate. If these drugs are administered together, monitor patients for daclatasvir-related adverse effects, such as headache, fatigue, nausea, and diarrhea. The manufacturer does not recommend daclatasvir dose reduction for adverse reactions.
Dalfopristin; Quinupristin: (Major) Avoid coadministration of ribociclib, a CYP3A4 substrate, with dalfopristin; quinupristin, a strong CYP3A4 inhibitor, as the systemic exposure of ribociclib may be increased resulting in an increase in ribociclib-related adverse reactions (e.g., neutropenia, QT prolongation); consider an alternative treatment with less potential for CYP3A inhibition. Ribociclib may also cause concentration-dependent QT prolongation, and the manufacturer of dalfopristin; quinupristin recommends avoidance with medications metabolized by CYP3A that may prolong the QTc interval.
Danazol: (Moderate) Use caution if coadministration of ribociclib with danazol is necessary, as the systemic exposure of ribociclib may be increased resulting in an increase in ribociclib-related adverse reactions (e.g., neutropenia, QT prolongation). Ribociclib is extensively metabolized by CYP3A4 and danazol is a moderate CYP3A4 inhibitor.
Dapsone: (Moderate) Use caution if coadministration of ribociclib with dapsone is necessary, as the systemic exposure of dapsone may be increased resulting in an increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dapsone is a CYP3A4 substrate.
Darifenacin: (Moderate) Use caution if coadministration of ribociclib with darifenacin is necessary, as the systemic exposure of darifenacin may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and darifenacin is a CYP3A4 substrate.
Darunavir: (Severe) Coadministration of ribociclib with darunavir is contraindicated, as elevated plasma concentrations of ribociclib may be associated with QT prolongation; exposure to darunavir may also increase. Ribociclib is extensively metabolized by CYP3A4 and darunavir is a strong CYP3A4 inhibitor; exposure to ribociclib may be increased. Additionally, ribociclib is a moderate CYP3A4 inhibitor and darunavir is a CYP3A4 substrate.
Darunavir; Cobicistat: (Severe) Coadministration of ribociclib with cobicistat is contraindicated, as elevated plasma concentrations of ribociclib may be associated with QT prolongation; exposure to cobicistat may also increase. Ribociclib is extensively metabolized by CYP3A4 and is a moderate CYP3A4 inhibitor; cobicistat is a moderate CYP3A4 inhibitor and CYP3A4 substrate. (Severe) Coadministration of ribociclib with darunavir is contraindicated, as elevated plasma concentrations of ribociclib may be associated with QT prolongation; exposure to darunavir may also increase. Ribociclib is extensively metabolized by CYP3A4 and darunavir is a strong CYP3A4 inhibitor; exposure to ribociclib may be increased. Additionally, ribociclib is a moderate CYP3A4 inhibitor and darunavir is a CYP3A4 substrate.
Dasabuvir; Ombitasvir; Pa |
